xen-d0501
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02233686)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Vanilloid receptorANTAGONIST
TRPV1 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707293 ↗
Also known as
- xen-d0501
- xen-d0501
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05353686 | Phase 2 | Feb 25, 2019 | Biomapas, Pila Pharma |
| NCT03278158 | Phase 2 | Sep 18, 2017 | Pila Pharma, University of Southern Denmark |
| NCT02233699 | Phase 2 | Jul 1, 2014 | Ario Pharma Ltd, Xention Ltd |
| NCT02233686 | Phase 2 | Feb 1, 2014 | Ario Pharma Ltd, Xention Ltd |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ario Pharma Ltd | For profit | 2 | 0 | 1 | 2014 |
| Pila Pharma | For profit | 2 | 2 | 1 | 2017 |
| Xention Ltd | For profit | 2 | 2 | 1 | 2014 |
| Biomapas | For profit | 1 | 0 | 1 | 2019 |
| University of Southern Denmark | Academic/Hospital | 1 | 0 | 1 | 2017 |
5 organizations
Page 1 / 1